Leiden University and Leiden University Medical Centre, institutions united by shared academic goals.
The distribution of multimorbidity among adults across different continents is a significant piece of information that is imperative for achieving the goals of Sustainable Development Goal 34, which prioritizes the reduction of premature deaths from non-communicable diseases. A significant presence of multiple illnesses correlates with elevated death rates and amplified demands on healthcare systems. check details A key goal was to examine the rate of multimorbidity across various WHO regions for the adult demographic.
We conducted a meta-analysis and systematic review of community-based surveys measuring the prevalence of multimorbidity in adults. A search of the PubMed, ScienceDirect, Embase, and Google Scholar databases was undertaken to locate studies published between January 1, 2000, and December 31, 2021. A random-effects model's output indicated the overall proportion of multimorbidity seen in adults. I was the tool used to determine the heterogeneity.
Analyzing numerical data using statistical techniques unveils valuable patterns and correlations. Subgroup and sensitivity analyses were conducted considering continents, age, gender, multimorbidity definitions, study periods, and sample sizes. The study's protocol details were registered with PROSPERO, specifically within the CRD42020150945 registry.
Across 54 countries, 126 peer-reviewed studies analyzed data from nearly 154 million individuals (321% male), showing a weighted mean age of 5694 years, with a standard deviation of 1084 years. Multimorbidity's global prevalence stands at 372% (a 95% confidence interval from 349% to 394%). Multimorbidity was most prevalent in South America (457%, 95% CI=390-525), followed by North America (431%, 95% CI=323-538%), Europe (392%, 95% CI=332-452%), and Asia (35%, 95% CI=314-385%). Subgroup data demonstrates a higher rate of multimorbidity amongst females (394%, 95% CI=364-424%) when compared to males (328%, 95% CI=300-356%), according to the study. A substantial percentage of the world's adult population aged above 60 years of age showed multimorbidity, with a prevalence of 510% (95% CI=441-580%). Multimorbidity's prevalence has substantially increased within the past two decades, but global adult prevalence appears to be maintaining a consistent level over the past ten years.
The observed differences in multimorbidity prevalence, broken down by geography, time, age, and sex, underscore the importance of considering demographic and regional factors. Based on insights concerning prevalence, urgent need exists for integrated and impactful intervention strategies aimed at older adults from South America, Europe, and North America. The widespread co-occurrence of various health conditions in South American adults highlights the critical need for immediate intervention strategies to minimize the health burden. Subsequently, the significant rise in multimorbidity cases during the last two decades points to an ongoing global health concern. Africa's low observed prevalence of chronic illness may be indicative of a large, undiagnosed population segment struggling with such conditions.
None.
None.
Pemafibrate is a highly potent and selective modulator of peroxisome proliferator-activated receptors. Is this agent demonstrably beneficial in mitigating the process of atherosclerosis?
The path forward remains unclear. Using pemafirate, this initial case report assesses the serial changes in coronary atherosclerosis in type 2 diabetic patients already taking high-intensity statins.
Hospitalization became necessary for the 75-year-old gentleman with peripheral artery disease, which was treated through endovascular procedures. A full year after the initial evaluation, a non-ST-elevation myocardial infarction (NSTEMI) transpired, requiring primary percutaneous coronary intervention (PCI) for the severe narrowing of the proximal right coronary artery segment. Because of his less-than-ideal management of low-density lipoprotein cholesterol (LDL-C) levels, using a moderate-intensity statin, a high-intensity statin (20 mg of atorvastatin) and 10 mg of ezetimibe were initiated, resulting in a very low LDL-C level of 50 mg/dL. Due to the one-year progression of the left circumflex artery following the NSTEMI, he was required to undergo further PCI procedures. In spite of an optimally controlled LDL-C level of 46 mg/dL, near-infrared spectroscopy and intravascular ultrasound imaging, performed after percutaneous coronary intervention, unveiled the presence of lipid-rich plaque, with a maximum lipid-core burden index (LCBI) of four millimeters.
His right coronary artery's non-culprit segment exhibited a blockage, specifically measured at 482. Considering the ongoing hypertriglyceridemia, with a triglyceride value of 248 mg/dL, 02 mg of pemafibrate was commenced, effectively decreasing triglycerides to 106 mg/dL. An investigation of coronary atheroma using NIRS/IVUS imaging was undertaken one year after the initial intervention. A decrease in the amplitude of attenuated ultrasonic signals was noted, coinciding with the formation of plaque calcification. check details The yellow signals experienced a reduction in frequency, and their maximum LCBI value was diminished.
The figure amounted to three hundred fifty-eight. In the ensuing period, the case has displayed no cardiovascular occurrences. Control of his LDL-C and triglyceride-rich lipoprotein levels is satisfactory.
Following the initiation of pemafibrate treatment, a reduction in coronary atheroma lipids, alongside a notable increase in plaque calcification, was noted. Pemafibrate's potential to counter atherosclerosis, particularly when used concurrently with statins, is illuminated by these findings.
The introduction of pemafibrate resulted in a reduction in the lipid content of coronary atheromas, along with an elevated rate of plaque calcification. Pemafibrate use, alongside a statin, potentially combats atherosclerosis, according to this finding.
The review explores the current status and outcomes of endovascular thrombectomy for thrombosed arteriovenous grafts (AVGs) and fistulas (AVFs).
Arteriovenous (AV) access enables end-stage renal disease (ESRD) patients to receive necessary hemodialysis treatments. check details Thrombosis impacting AV hemodialysis access can either delay the scheduled treatment or ultimately necessitate the transition to dialysis catheter access. Endovascular procedures are now the preferred method of treatment for thrombosed vascular access, surpassing surgical options. Treatment protocols encompass the removal of thrombi from the AV circulatory system and the remediation of the underlying structural defect, including instances of anastomotic constriction. Fibrinolytic agents are administered to dissolve thrombi (thrombolysis) by way of infusion catheters or pulse injector devices. Thrombectomy, which entails the physical removal of a thrombus, is carried out through the use of embolectomy balloon catheters, rotating baskets or wires, rheolytic instruments and aspiration mechanisms. Methods like cutting balloon angioplasty, drug-eluting balloon angioplasty, and stent placement are additionally employed in the management of stenoses within the AV circuit. The procedures may lead to several complications, including, but not limited to, vessel rupture, arterial embolism, pulmonary embolism (PE), and paradoxical embolism that can reach the brain.
Based on a thorough review of electronic databases like PubMed and Google Scholar, this narrative review article was produced.
Knowledge of thrombectomy procedures and their potential adverse outcomes is essential for optimal patient care in thrombosed arteriovenous access.
Effective patient management involving thrombosed AV access necessitates a deep understanding of thrombectomy procedures and the various possible complications.
The use of acupuncture to treat hypertension has been extensive across a number of nations. However, the bibliometric analysis of acupuncture's use worldwide for hypertension is often ambiguous. Subsequently, the study's goal was to investigate the current state and recent progress in the global application of acupuncture to hypertension over the past 20 years, utilizing CiteSpace (58.R2). From 2002 to 2021, the Web of Science (WOS) database analyzed research articles on acupuncture's application in hypertension treatment. Our CiteSpace analysis quantified publications, cited journals, nations/regions, organizations, authors, cited authors, citations, and the associated keywords. From 2002 to 2021, the documentation reached a total of 296 entries. The gradual increase in the quantity and frequency of annual publications was observed. Circulation led the citation count and centrality rankings, followed by Clin Exp Hypertens (Clinical and Experimental Hypertension), which achieved a strong second position. China's output of publications was the greatest among all countries and regions, and notably, the five largest institutions were all situated in China. Cunzhi Liu's substantial authorship contrasted with P. Li's work, which received the most citations. XF Zhao's initial contribution, an article within the cited references classification, was produced. The dataset analysis showcased a high frequency and centrality of 'electroacupuncture' keywords, indicating a prominent presence and acceptance of this treatment in this domain. In the context of hypertension treatment, electroacupuncture shows a beneficial effect, specifically regarding blood pressure reduction. In light of the diverse applications of electroacupuncture frequencies in research, the correlation between the frequency and the therapeutic outcomes should be a subject of heightened investigation. This bibliometric analysis of clinical acupuncture studies for hypertension during the last two decades illuminates the current state and trajectory of research, thereby helping researchers identify impactful areas and new investigative paths.